Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study

• Published in: BMC cancer 2018-10, Vol.18 (1), p.957-7, Article 957
• Main Authors: Dote, Satoshi, Itakura, Shoji, Kamei, Kohei, Hira, Daiki, Noda, Satoshi, Kobayashi, Yuka, Terada, Tomohiro
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Aged; Analysis; Anti-EGFR antibody; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Cancer; Cancer therapies; Cetuximab; Cetuximab - adverse effects; Cetuximab - therapeutic use; Chemotherapy; Cohort analysis; Cohort Studies; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Complications and side effects; Cytotoxicity; Drug dosages; Drug therapy; Epidermal growth factor; Epidermal growth factor receptors; Female; Fluorouracil - therapeutic use; Glossitis; Humans; Immunoglobulins; Immunotherapy; Leucovorin - therapeutic use; Male; Metastasis; Middle Aged; Monoclonal antibodies; Mucositis; Mucous membrane; Neutropenia; Oncology; Oral mucositis; Organoplatinum Compounds - therapeutic use; Panitumumab; Panitumumab - adverse effects; Panitumumab - therapeutic use; Patients; Pharmacists; Quality of life; Retrospective Studies; Risk factors; Skin; Stomatitis; Stomatitis - chemically induced; Studies; Targeted cancer therapy
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-4862-z

Chemotherapy-induced oral mucositis impairs the quality of life. The difference in severity of oral mucositis between different anti-epidermal growth factor receptor (EGFR) antibodies combined with cytotoxic drugs in colorectal cancer is unclear. The aim of this study was to investigate the differences in oral mucositis between panitumumab (Pmab) and cetuximab (Cmab) combined with 5-fluorouracil (5-FU). We conducted a retrospective cohort study. A total of 75 colorectal cancer outpatients treated with an anti-EGFR antibody combined with FOLFOX, FOLFIRI, or 5-FU/leucovorin as the first- to third-line treatment were included. The primary endpoint was the incidence of grade 2-3 oral mucositis. The secondary endpoint was the time to onset of oral mucositis. We also compared the incidence of toxicities of interest, skin toxicity, hypomagnesaemia and neutropenia, and time to treatment failure (TTF) between the two groups. Thirty-two patients treated with Pmab and 43 patients treated with Cmab were evaluated. Patient characteristics were similar between the two groups. The incidence of grade 2-3 oral mucositis was significantly higher with Pmab than with Cmab (31.3% vs 9.3%, P